Logo Logo
Hilfe
Hilfe
Switch Language to English

Alexopoulos, Panagiotis; Gleixner, Lena-Sophie; Werle, Lukas; Buhl, Felix; Thierjung, Nathalie; Giourou, Evangelia; Kagerbauer, Simone M.; Gourzis, Philippos; Kuebler, Hubert; Grimmer, Timo; Yakushev, Igor; Martin, Jan; Kurz, Alexander und Perneczky, Robert (2018): Plasma levels of soluble amyloid precursor protein beta in symptomatic Alzheimer's disease. In: European Archives of Psychiatry and Clinical Neuroscience, Bd. 268, Nr. 5: S. 519-524

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

The established biomarkers of Alzheimer's disease (AD) require invasive endeavours or presuppose sophisticated technical equipment. Consequently, new biomarkers are needed. Here, we report that plasma levels of soluble amyloid precursor protein beta (sAPP beta), a protein of the initial phase of the amyloid cascade, were significantly lower in patients with symptomatic AD (21 with mild cognitive impairment due to AD and 44 with AD dementia) with AD-typical cerebral hypometabolic pattern compared with 27 cognitively healthy elderly individuals without preclinical AD. These findings yield further evidence for the potential of sAPP beta in plasma as an AD biomarker candidate.

Dokument bearbeiten Dokument bearbeiten